Considering the need for mandatory treatment in stage 5 CKD patients regarding erythropoietin, phosphorus and potassium binders, and renal replacement therapy, it is unlikely that there will be a prolonged delay of over one year. The gene discussed is EPO; the disease is chronic kidney disease.